Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

NCT05942911 is registered in ClinicalTrials.gov with Incannex Healthcare Ltd as lead sponsor.

NCT NCT05942911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05942911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Blinded, Randomised, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
Lead sponsor
Incannex Healthcare Ltd
Phase
Phase 2
Overall status
Terminated
Start date
November 22, 2023
Completion date
October 28, 2025
Enrollment
20 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis